Page last updated: 2024-10-23

bisoprolol and Stroke

bisoprolol has been researched along with Stroke in 13 studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

Research Excerpts

ExcerptRelevanceReference
"To examine the effects of combination with levamlodipine and bisoprolol on stroke in rats."7.79Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats. ( Gui, H; Guo, YF; Huang, GZ; Liu, JG; Liu, X; Yang, YL; Zhang, JM, 2013)
"The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol."7.79Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013)
"The RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial will enrol 160 participants with a prospective, randomised, open-label, blinded end point design comparing initial rate control with digoxin or bisoprolol."5.24A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. ( Calvert, M; Deeks, JJ; Griffith, M; Kirchhof, P; Kotecha, D; Lip, GY; Mehta, S; Slinn, G; Stanbury, M; Steeds, RP; Townend, JN, 2017)
"To examine the effects of combination with levamlodipine and bisoprolol on stroke in rats."3.79Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats. ( Gui, H; Guo, YF; Huang, GZ; Liu, JG; Liu, X; Yang, YL; Zhang, JM, 2013)
"The use of metoprolol and atenolol is associated with increased risks of postoperative stroke, compared with bisoprolol."3.79Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. ( Ashes, C; Beattie, WS; Hare, GM; Judelman, S; Mazer, CD; Tait, G; Wijeysundera, DN, 2013)
"Left ventricular hypertrophy was diagnosed using the Sokolow-Lyon indices."1.48Left ventricular hypertrophy diagnosed after a stroke: a case report. ( Kanyal, R; Umeojiako, WI, 2018)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.69)29.6817
2010's11 (84.62)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Iwano, T1
Toda, H1
Nakamura, K1
Shimizu, K1
Ejiri, K1
Naito, Y1
Mori, H1
Masuda, T1
Miyoshi, T1
Yoshida, M1
Hikasa, Y1
Morimatsu, H1
Ito, H1
Kotecha, D1
Calvert, M1
Deeks, JJ1
Griffith, M1
Kirchhof, P1
Lip, GY1
Mehta, S1
Slinn, G1
Stanbury, M1
Steeds, RP1
Townend, JN1
DiFrancesco, JC1
Umeojiako, WI1
Kanyal, R1
Gui, H1
Guo, YF1
Liu, X1
Zhang, JM1
Yang, YL1
Huang, GZ1
Liu, JG1
Bradley, A1
Sheridan, P1
Ashes, C2
Judelman, S2
Wijeysundera, DN1
Tait, G2
Mazer, CD2
Hare, GM2
Beattie, WS2
Eisenach, JC1
Wicker, JF1
Bronheim, D1
Wijeysundera, D1
Lu, HT1
Nordin, R1
Othman, N1
Choy, CN1
Kam, JY1
Leo, BC1
Ramsamy, G1
Goh, TH1
van Lier, F1
Schouten, O1
Hoeks, SE1
van de Ven, L1
Stolker, RJ1
Bax, JJ1
Poldermans, D1
Leizorovicz, A1
Lechat, P1
Cucherat, M1
Bugnard, F1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy[NCT02391337]Phase 4161 participants (Actual)Interventional2016-12-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Ambulatory Heart-rate.

24 hour ambulatory heart-rate. (NCT02391337)
Timeframe: Within 12 months

Interventionbpm (Mean)
Beta-blocker73.7
Digoxin78.9

B-type Natriuretic Peptide (BNP) at 6 Months.

B-type natriuretic peptide (BNP) at 6 months. (NCT02391337)
Timeframe: 6 months

Interventionng/L (Median)
Beta-blocker1209
Digoxin1057.5

Cardiovascular Events

Number of Participants with hospital admissions for cardiovascular events. (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker12
Digoxin2

Composite Functional Status Measures- 6 Minute Walking Distance at 12 Months.

Composite functional status measures- 6 minute walking distance at 12 months. (NCT02391337)
Timeframe: 12 months

Interventionmetres (Median)
Beta-blocker329
Digoxin366

Diastolic Function- Measured by the E/e'.

"The above parameters will be measured using echocardiography and diastolic indices.~E/e' - the ratio between early mitral inflow velocity and mitral annular early diastolic velocity." (NCT02391337)
Timeframe: 12 months

InterventionRatio of E/e' (Mean)
Beta-blocker10.8
Digoxin10.8

Drug Discontinuation Rate Within 12 Months.

Number of participants requiring drug discontinuation due to adverse reactions. (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker9
Digoxin2

Hospital Admission Rate

A composite of adverse clinical events (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Beta-blocker19
Digoxin11

Left Ventricular Ejection Fraction

The above parameters will be measured using echocardiography and diastolic indices (NCT02391337)
Timeframe: 12 months

Interventionpercentage of ejection fraction (Mean)
Beta-blocker59.8
Digoxin59.7

Number of Participants With Unplanned Hospital Admissions.

Number of Participants with Unplanned Hospital Admissions. (NCT02391337)
Timeframe: During the 12 month follow-up period.

InterventionParticipants (Count of Participants)
Beta-blocker19
Digoxin11

Patient Reported Outcomes (EQ-5D-5L)

"As assessed using the EQ-5D-5L summary index questionnaires at both 6 and 12 months.~The range for summary index is from -0.594=worst score to 1=best score" (NCT02391337)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Beta-blocker0.62
Digoxin0.66

Patient Reported Outcomes- (AFEQT) at 12 Months.

As assessed using the AFEQT overall score at 12 months. The range for AFEQT overall score is from 0= complete disability to 100=no disability. (NCT02391337)
Timeframe: 12 months

Interventionscore on a scale (Mean)
Beta-blocker68.1
Digoxin75.6

Patient Reported Quality of Life (SF-36)

"Patient-reported outcomes as assessed by the SF-36 questionnaire physical component score.~The physical component score ranges from 0-100 where higher value indicates better outcome." (NCT02391337)
Timeframe: Primary outcome at 6 months timepoint.

Interventionscore on a scale (Mean)
Beta-blocker29.7
Digoxin31.9

Patient Reported Outcomes (SF36) Version 2 at 12 Months.

As assessed using the SF-36 version 2 global and specific scores at 12 months. All domains presented are between 0 to 100 scale where the higher score indicates better outcomes. (NCT02391337)
Timeframe: 12 months

,
Interventionscore on a scale (Mean)
Physical Component SummaryMental Component SummaryPhysical Function Domain ScoreRole Limitation Due to Physical Domain scoreRole Limitation Due to Emotional Problems Domain scoreSocial Functioning Domain ScoreMental Health DomainEnergy/Vitality Domain ScorePain ScoreGeneral Health Perception Domain Score
Beta-blocker29.451.327.53240.743.351.84241.939.6
Digoxin32.553.631.53745.245.651.347.140.542.8

Retention of Participants

Convenience, compliance and cross-over data (NCT02391337)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Death71940422Death71940423Lost to follow-up71940422Lost to follow-up71940423Withdrawn consent71940422Withdrawn consent71940423
yesNo
Beta-blocker7
Digoxin4
Beta-blocker73
Digoxin77
Beta-blocker0
Digoxin2
Beta-blocker80
Beta-blocker1
Beta-blocker79
Digoxin79

Reviews

1 review available for bisoprolol and Stroke

ArticleYear
Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.
    American heart journal, 2002, Volume: 143, Issue:2

    Topics: Adrenergic beta-Antagonists; Bisoprolol; Female; Heart Failure; Hospitalization; Humans; Male; Middl

2002

Trials

3 trials available for bisoprolol and Stroke

ArticleYear
Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study.
    Journal of cardiology, 2021, Volume: 78, Issue:5

    Topics: Aged; Atrial Fibrillation; Bisoprolol; Humans; Postoperative Complications; Risk Factors; Stroke; Tr

2021
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.
    BMJ open, 2017, Jul-20, Volume: 7, Issue:7

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolo

2017
Impact of prophylactic beta-blocker therapy to prevent stroke after noncardiac surgery.
    The American journal of cardiology, 2010, Jan-01, Volume: 105, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Dose-Response Relationship, Drug; Female; Humans; Inc

2010

Other Studies

9 other studies available for bisoprolol and Stroke

ArticleYear
Artery of Percheron ischaemic stroke revealed by brain MRI DWI/ADC sequences.
    BMJ case reports, 2017, Dec-02, Volume: 2017

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Brain Ischemia; Cerebral Arteries; Diffusi

2017
Left ventricular hypertrophy diagnosed after a stroke: a case report.
    Journal of medical case reports, 2018, Mar-22, Volume: 12, Issue:1

    Topics: Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Cardiomyopathy, Hypertrophic; Chest Pain; Co

2018
Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats.
    CNS neuroscience & therapeutics, 2013, Volume: 19, Issue:3

    Topics: Animals; Antihypertensive Agents; Baroreflex; Bisoprolol; Drug Therapy, Combination; Heart Rate; Mal

2013
Atrial fibrillation.
    BMJ (Clinical research ed.), 2013, Jun-17, Volume: 346

    Topics: Aged; Antihypertensive Agents; Anxiety; Atrial Fibrillation; Bisoprolol; Comorbidity; Diabetes Melli

2013
Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients.
    Anesthesiology, 2013, Volume: 119, Issue:4

    Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atenolol; Bisoprolol; Cohort Studies; Female; Humans;

2013
Patient safety: anesthesiology contributions and supplements to the American Society of Anesthesiologists' Annual Meeting.
    Anesthesiology, 2013, Volume: 119, Issue:4

    Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post

2013
Does β selectivity really affect outcome?
    Anesthesiology, 2014, Volume: 120, Issue:5

    Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post

2014
In reply.
    Anesthesiology, 2014, Volume: 120, Issue:5

    Topics: Adrenergic beta-1 Receptor Antagonists; Atenolol; Bisoprolol; Female; Humans; Male; Metoprolol; Post

2014
Biatrial thrombi resembling myxoma regressed after prolonged anticoagulation in a patient with mitral stenosis: a case report.
    Journal of medical case reports, 2016, Aug-10, Volume: 10, Issue:1

    Topics: Antihypertensive Agents; Atrial Fibrillation; Bisoprolol; Diagnosis, Differential; Directive Counsel

2016